These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17212321)

  • 1. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

  • 2. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug costs should be based on health economic benefits. A new law on drug benefits requires studies of health economic effects].
    Berggren F
    Lakartidningen; 2003 Jul; 100(30-31):2446-8. PubMed ID: 12914141
    [No Abstract]   [Full Text] [Related]  

  • 4. [Priorities by the board of drug benefits--guidelines clarify. Clinical trials are not sufficient for decisions on subsidizing].
    Carlsson P
    Lakartidningen; 2003 Jul; 100(30-31):2428-9. PubMed ID: 12914137
    [No Abstract]   [Full Text] [Related]  

  • 5. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].
    Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economics--what the nephrologist should know.
    Palmer AJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1038-41. PubMed ID: 15840678
    [No Abstract]   [Full Text] [Related]  

  • 8. Valuing reduced antibiotic use for pediatric acute otitis media.
    Meropol SB
    Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving healthy people 2010 immunization goals: proceedings of a national conference. Chapel Hill, North Carolina: October 12-13, 2001. Economics of immunization.
    Sisk J
    Clin Ther; 2003; 25 Suppl A():A9-A17. PubMed ID: 12928064
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [National economic consequences of vaccines].
    Bergman A; Persson U
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficiency frontier approach to economic evaluation: will it help German policy making?
    Brouwer WB; Rutten FF
    Health Econ; 2010 Oct; 19(10):1128-31. PubMed ID: 20641141
    [No Abstract]   [Full Text] [Related]  

  • 17. [The Dental and Pharmaceutical Benefits Agency misinterpret its mission].
    Carlsson U
    Lakartidningen; 2010 Jun 30-Jul 20; 107(26-28):1717; discussion 1718. PubMed ID: 20701155
    [No Abstract]   [Full Text] [Related]  

  • 18. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What is medical economics?].
    Szucs TD
    Med Klin (Munich); 1996 Jan; 91(1):49-53. PubMed ID: 8839203
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.